InsidersTradesSigma
현대바이오 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 현대바이오 stock price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 현대바이오 has recorded 49 insider filings. Market capitalisation: €852.8bn. The latest transaction was disclosed on 12 June 2026 (Other). Among the most active insiders: 씨앤팜. All data is free.
49
Insider Decl.
0
Thresholds
·
1 ops.
Buy Volume
·
4 ops.
Sell Volume
4Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,161 of 25,571 companies
16.5
score / 100
Value22
Quality11
FCF yld-5.2%
Earn yld-3.1%
EV/EBITDA·
ROE-19%
Gross mgn6.9%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 June 2026
Declarations49 total
25 of 49 declarations